Vanda Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Vanda Pharmaceuticals has a total shareholder equity of $541.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $645.1M and $103.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$376.26m |
| Equity | US$541.22m |
| Total liabilities | US$103.89m |
| Total assets | US$645.12m |
Recent financial health updates
No updates
Recent updates
Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids
Sep 05Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
Aug 08Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
Jun 18Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
Apr 05Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Feb 15
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
Feb 13Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement
Feb 10News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts
Nov 11One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be
May 12Financial Position Analysis
Short Term Liabilities: VNDA's short term assets ($432.4M) exceed its short term liabilities ($89.1M).
Long Term Liabilities: VNDA's short term assets ($432.4M) exceed its long term liabilities ($14.8M).
Debt to Equity History and Analysis
Debt Level: VNDA is debt free.
Reducing Debt: VNDA has not had any debt for past 5 years.
Debt Coverage: VNDA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: VNDA has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 09:03 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vanda Pharmaceuticals Inc. is covered by 21 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Aegis Capital Corporation |
| null null | Argus Research Company |
| Olivia Brayer | BofA Global Research |